AKT1 and lung cancer: Previous preclinical studies showed that dual inhibition of PI3K/Akt/mTOR and MAPK/ERK pathways by combining two different small molecule kinase inhibitors led to more efficient growth inhibition than single pathway inhibition in both breast and lung cancers [26, 30].